D.E. Shaw & Co
RPRX

D.E. Shaw & Co’s Repros Therapeutics Inc. RPRX Stock Holding History

D.E. Shaw & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-239,548
Closed -$232K – 3754
2016
Q1 		$232K Sell
239,548
-30,561
-11% -$29.8K ﹤0.01% 3131
2015
Q4 		$327K Buy
270,109
+159,870
+145% +$513K ﹤0.01% 3328
2015
Q3 		$819K Sell
110,239
-12,484
-10% -$95.5K ﹤0.01% 2738
2015
Q2 		$877K Buy
122,723
+56,142
+84% +$437K ﹤0.01% 2801
2015
Q1 		$572K Buy
66,581
+33,095
+99% +$296K ﹤0.01% 2970
2014
Q4 		$334K Sell
33,486
-3,325
-9% -$28.4K ﹤0.01% 3590
2014
Q3 		$365K Sell
36,811
-54,272
-60% -$804K ﹤0.01% 3567
2014
Q2 		$1.58M Sell
91,083
-22,227
-20% -$362K ﹤0.01% 2520
2014
Q1 		$2.01M Sell
113,310
-84,179
-43% -$1.63M ﹤0.01% 2390
2013
Q4 		$3.61M Buy
197,489
+30,064
+18% +$568K ﹤0.01% 1970
2013
Q3 		$4.49M Buy
+167,425
New +$3.59M 0.01% 1702

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

D.E. Shaw & Co's RPRX Position: Q2 2016 in Review

D.E. Shaw & Co sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 239,548 shares — an estimated $232K sold.

D.E. Shaw & Co first reported a position in RPRX in Q3 2013 and held it in 11 quarters. The position peaked at $4.49M in Q3 2013. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

  • D.E. Shaw & Co reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
  • D.E. Shaw & Co sold 239,548 Repros Therapeutics Inc. shares in Q2 2016, an estimated $232K.
  • D.E. Shaw & Co first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 11 quarters.
  • D.E. Shaw & Co's Repros Therapeutics Inc. position peaked at $4.49M in Q3 2013.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on D.E. Shaw & Co's 13F filing for Q2 2016, filed 15 Aug 2016.